|

Durvalumab (Cohort 1-3) Clinical Trials

1 actively recruiting trial across 1 location

Also known as: Imfinzi

Pipeline

Phase 1/2: 1

Top Sponsors

  • Noah Hahn, M.D.1

Indications

  • Urothelial Carcinoma1
  • Bladder Cancer1
  • Cancer1

Phoenix, Arizona1 trial

Modern Immunotherapy in BCG-Unresponsive, BCG-Relapsing and High Risk BCG-Naive Non-Muscle Invasive Urothelial Carcinoma of the Bladder

BCG Oncology

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.